
During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical evidence inform subsequent-line treatment selection for metastatic clear cell renal cell carcinoma.
Choosing Second-Line Therapy for Metastatic Kidney Cancer
Case Scenario 1: A 50-year old male with relapse of metastatic RCC
January 2014
April 2016